FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System

AccelSPINE has received U.S. Food and Drug Administration clearance on its Picasso II system.

Advertisement

Picasso II is intended to immobilize and stabilize spinal segments as a supplement to fusion during the treatment of acute and chronic instabilities or deformities of the spine. It is an addition to the company’s Picasso product line.

 

AccelSPINE is a national medical device company that designs, develops and manufactures spinal implants and instruments.

More Articles on Devices:

Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.